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Introduction 
Cutaneous lymphomas comprise a heterogeneous group of clonal 
lymphoproliferative disorders originating in the skin. They are differenti-
ated analogous to the structure of the lymphatic systems in cutaneous B 
and T cell lymphomas [1,2]. Recently, the development of immunhisto-
chemistry allowed a more sophisticated classification of these neoplasms 
(table 1) [3]. 
Another disease closely related to cutaneous T cell lymphomas is 
lymphomatoid papulosis. The cutaneous lesions of the latter lymphoprolif-
erative disorder consist of CD-30-positive blastic T lymphocytes. The 
papulonodular eruptions resemble pityriasis lichenoides et varioliformis 
acuta (Mucha-Haberman disease) clinically, but lymphoma histologically 
[4]. A clonal rearrangement of the T cell receptor beta-chain had been 
demonstrated [5]. The clinical course is rather benign. The disease is 
recurrent, but sometimes self-healing. However, there is an as yet undefined 
relationship to Hodgkin's lymphoma [6]. 
Low-grade peripheral T cell lymphomas represent the majority of 
cutaneous lymphomas. The most common diseases in this group include 
mycosis fungoides and its leukemic counterpart, the Sezary syndrome. The 
first symptoms of these cutaneous lymphomas appear in the skin. In the 
early stages, flat lesions such as macules and patches or slightly elevated 
lesions such as papules or plaques are dominating, whereas in the more 
advanced stages also larger lesions such as nodules or tumors develop [1,2]. 
The early stage skin lesions are often misdiagnosed as chronic contact 
dermatitis or eczema, because they present only nonspecific histological 
features such as spongiosis and sparse infiltrate of mononuclear cells. 
HePC in Patients with Cutaneous Lymphomas 
Table 1. Histological classification of malignant cutaneous lymphomas 
Cutaneous T cell lymphoma 
A Prethymic and thymic T cell lymphoma 
Lymphoblastic 
B Peripheral T cell lymphoma 
I Low grade 
1 Chronic lymphatic or polymorphocytic leukemia 
2 Small cerebriform (mycosis fungoides, Sezary syndrome) 
3 Lymphoepitheloid (Lennert's) lymphoma 
4 Angioimmunoblastic lymphoma 
5 T-zone lymphoma 
6 Pleomorphic, small cell lymphoma 
II High-grade 
1 Pleomorphic, medium and large cell lymphoma 
2 Immunoblastic lymphoma 
3 Large cell anaplastic lymphoma 
III Unclassifiable 
Cutaneous B cell lymphoma 
I Low grade 
1 Lymphocytic lymphoma 
2 Lymphoplasmacytoid lymphoma 
3 Centrocytic lymphoma 
4 Centroblastic-centrocytic lymphoma 
II High-grade 
1 Centroblastic lymphoma 
2 Immunoblastic lymphoma 
3 Lymphoblastic lymphoma 
III Unclassifiable 
Lymphomatoid papulosis 
However, repeated biopsies may help to identify characteristic histological 
criteria for the diagnosis of cutaneous T cell lymphoma. They include an 
epidermotropic, band-like mononuclear infiltrate, or epidermal collections 
of lymphatic cells (Pautrier's microabscess) [1,2]. 
Cutaneous lymphomas are usually slowly progressing. There are often 
years between the first appearance of skin lesions and the definite diagnosis. 
Lymph nodes and other organs are involved in advanced stages, after the 
T cells have lost their epidermotropic distribution pattern and start to form 
nodules or tumors. 
There have been attempts to apply aggressive treatment modalities 
such as high-dose chemotherapy or radiation. The long-term results, how-
ever, were disappointing. A recently published randomized clinical trial 
failed to show an increased survival for a high-dose chemotherapy plus 
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radiotherapy compared to stage-adapted therapy [7]. As a consequence, the 
treatment of cutaneous lymphomas is palliative. A topical therapy is 
preferred as long as possible. For the early stages, local application of 
steroids such as betametasone or photochemotherapy (psoralen plus U V -
A) are used [8]. Advanced stages require the topical application of cyto-
toxic drugs such as carmustine ( B C N U ) or mechlorethamine (NH2) [9]. 
Interferon-alpha seems to be an effective cytokine for the therapy of 
cutaneous T cell lymphoma [10]. Systemic involvement is treated by 
chemotherapy or radiation in case of single lesions. 
However, long-term treatment with these drugs results in various 
dose-limiting side effects. Steroids induce atrophy of the dermis and 
epidermis [11]. Photochemotherapy is associated with an increased inci-
dence of epidermal neoplasia such as basal cell carcinoma [12]. Finally, 
cutaneous T cell lymphomas often lose their responsiveness to these topical 
drugs. Therefore, therapeutic alternatives are required for cutaneous 
lymphomas. Epidermotropism and long-lasting restriction to the skin are 
pathophysiological properties which suggest further development of topical 
therapy. Since lymphatic tumor cells are suitable targets for phospholipid 
derivates [13, 14], this new group of cytotoxic drugs is a candidate for the 
therapy of these lymphoproliferative disorders. 
The ointment preparation of hexadecylphosphocholine [15], an 
alkylphosphocholine, allowed us to explore this class of new drugs in a 
phase I/I I clinical trial in patients with cutaneous lymphomas. 
Patients, Materials and Methods 
Patients 
The study protocol was approved by the ethical committee of the University of 
Wurzburg. Written informed consent was obtained from each patient. Patients with histolog-
ically proven cutaneous lymphoma were included if they did not require systemic therapy. 
There had to be measurable or evaluable involvement of the skin which was documented by 
photography. Patients with leukopenia, anemia, severe cardiac, hepatic or renal disease were 
excluded. No systemic chemotherapy was allowed during the trial and 4 weeks prior to the 
entry of the study. Topical steroids and photochemotherapy (PUVA) of indicator lesions were 
not allowed for a period of at least 2 weeks before study entry. Prior to and during the 
application of topical hexadecylphosphocholine standard laboratory parameters were moni-
tored. In addition, serum was collected for determination of circulating levels of hexade-
cylphosphocholine. In the case of a clinical complete response, a biopsy was performed to 
verify the histological appearance of hexadecylphosphocholine induced tumor regression. 
Hexadecylphosphocholine Ointment (Miltefosine) 
The ointment used in this trial was supplied by ASTA Pharma A G , Frankfurt, F R G . It 
contains 6% of hexadecylphosphocholine and has been used for topical treatment of skin 
metastasis of breast cancer in prior studies [15]. 
Area of Treatment 
For the first 6 patients the treated area was limited to 200 cm2. In subsequent patients, 
the treated area was extended stepwise up to a maximum area of 3,200 cm 2 in the present 
group of patients. 
Dosage and Duration of Therapy 
During the first week the ointment was applied once daily, in the following 7 weeks 
twice daily in the defined area. The dosage was approximately one drop per 10 cm 2 lesion 
area. The initial duration of therapy was 8 weeks. In the case of partial or minor response 
continuation for additional 4 weeks was allowed. 
Criteria of Response 
A complete response (CR) is defined as the complete disappearance of all lesions in the 
treated area for at least 4 weeks. A partial response (PR) is defined as equal to or greater than 
a 50% decrease of all lesions in the treated area, lasting for at least 4 weeks, without any 
appearance of new lesions. Minor response (MR) is a regression of cutaneous lesions by at 
least 26% and maximal 49%. Stable disease (SD) is defined as no increase or decrease of 
cutaneous lesions by more than 25%. Progressive disease (PD) is at least a 26% increase of 
measured lesions. In case of clinically diagnosed CR, histological verification was requested. 
Histological Monitoring 
In each patient, a biopsy was taken to confirm the clinical diagnosis. Standard 
histological staining (HE, PAS, Giemsa) was used in formalin-embedded tissues. Snap-frozen 
biopsy specimens were stained with a panel of monoclonal antibodies (APAAP technique). An 
additional biopsy was taken in patients demonstrating a complete clearing of treated cuta-
neous lesions. 
Results 
Response 
Fifteen patients with histologically proven cutaneous lymphomas were 
treated. Nine were male, 6 were female. The mean age was 60 years (range 
32-86 years). Eight patients presented with mycosis fungoides of different 
stages (table 2a). Five patients had cutaneous B cell lymphoma (table 2b); 
staging revealed no extracutaneous tumor manifestation in 4 of them. One 
patient with low-grade B cell lymphoma (lymphocytic immunocytoma) 
presented nodular infiltrates of a chronic lymphocytic B cell leukemia 
without anemia or thrombocytopenia (fig. 2a). In addition, 2 patients with 
lymphomatoid papulosis were treated. 
In the group of cutaneous T cell lymphoma patients, 7 patients were 
evaluable for response. Two complete (fig. la/b), two partial remission, two 
stable disease and one progression were observed, clinically (table 2a). In 
the 5 patients with B-cell lymphoma, one complete (fig. 2a, b), three partial 
remissions and one stable disease were seen (table 2b). Both patients with 
lymphomatoid papulosis (table 2c) showed a complete clearing of the 
lesions (complete remission). 
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Table 2. Patients' characteristics 
Patient Age 
Years 
Sex Diagnosis Stage [3] Response 
a Cutaneous T cell lymphoma patients 
K.J. 
G.A. 
G.C. 
T .H. 
S.J. 
N.E. 
L .H. 
Z .G. 
53 
76 
86 
60 
32 
50 
32 
54 
b B cell lymphomas 
R.P. 77 
K . H . 79 
S.M. 77 
W.M. 41 
S.A. 74 
c Lymphomatoid papulosis 
L.A. 77 
W.E. 36 
M 
M 
M 
M 
M 
M 
M 
F 
M 
M 
F 
F 
F 
M F 
M F 
M F 
M F 
M F 
M F 
M F 
M F 
cb-cc 
cc 
cb 
cb-cc 
cb-cc 
LP 
LP 
IA 
IVA 
IA 
IIA 
IA 
IA 
IA 
IIB 
SD 
SD 
CR 
PD 
n.e. 
PR 
CR 
PR 
PR 
CR 
SD 
PR 
PR 
CR 
CR 
M F = Mycosis fungoides; 
lymphomatoid papulosis. 
n.e. = not evaluable; cb = centroblastic; cc = centrocytic; LP = 
Although the calculation of an overall response rate is critical due to 
limited number and the heterogeneous group of patients, we indicate an 
objective response rate (partial and complete response) of 71% (10/14) for 
the cutaneous lymphoma patients treated in this study. 
One patient presented a keloid at a biopsy site before starting hexade-
cylphosphocholine therapy. In this patient, an impressive regression of the 
keloid was observed during the topical treatment. 
Toxicity 
The topical application was tolerated without any local or systemic 
side effects in 4 patients. A slight erythema with fine scaling and a discrete 
atrophy of the skin was a common finding during the last 4 weeks of 
therapy in 9 patients. However, 2 patients presented a striking, sharply 
demarcated erythema in the treated area. They reported local itching and 
'burning'. In these patients, the therapy was discontinued. These side effects 
were observed in the intertriginous areas (elbow and groin) in both patients 
suggesting an occlusive effect on the topical medication. Symptoms re-
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Fig. la. h. Clinical appearance of a mycosis fungoides lesion prior to and after 8 weeks 
of miltefosine treatment (complete response) which shows wrinkling and the thin, almost 
transparent aspect of the skin with postinflammatory hypcrpigmentation posttreatment (h). 
solved within a few days while the local inflammation was treated by 
topical steroids. It should be emphasized that the local application of 
hexadecylphosphocholine did not have any impact on hematopoesis, renal 
or hepatic function documented by standard laboratory tests. Furthermore, 
none of the patients noted any subjective complaints. 
Histological Monitoring 
In all patients treated in this study, pretreatment biopsies were taken 
to confirm the diagnosis. In 5 patients with complete remission and 1 
patient with stable disease, a second biopsy was taken from the treated area 
after 8 weeks of treatment. In all biopsies taken from a treated area, a 
thinning of the epidermis was observed suggesting an inhibitory effect on 
epidermal cell proliferation. 
In the patients presenting a complete response clinically, the histologi-
cal section showed a significant decrease of the number of infiltrating 
lymphocytes in the epidermis and the upper dermis. However, the infiltrates 
Fig. 2ci. b. Cutaneous eruptions of a patient with chronic lymphocytic B cell leukemia 
prior to and after 8 weeks of miltefosine treatment (complete response). Note postinflamma-
tory hyperpigmentation and continuing teleangiectasias. 
in the deeper dermis were still present (fig. 3a/b). Thus, the clinical C R 
turned out to be PR with regard to histology. 
Discussion 
The clinical management of cutaneous lymphoma remains a challeng-
ing problem in dermatological oncology. The low prevalence and the highly 
variable natural history, with episodes of spontaneous remissions and 
exacerbations raised the question about the optimal management of these 
patients. After a controversial discussion, nonaggressive, stage-adapted, 
sequential application of topical therapies are preferred first-line treatment 
modalities. In addition, the advanced mean age of these patients suggests a 
moderate well-tolerable therapy. The group of patients treated in our study 
with a mean age of sixty years is rather representative for patients with 
cutaneous lymphoma [ 16]. However, there are only a very limited number 
of mild therapeutic alternatives available which include topical steroids and 
photochemotherapy with P U V A (psoralen plus U V - A ) . More aggressive is 
Fig. 3a, b. Histology ( H E ) of a mycosis fungoides lesion prior to (a) and after S weeks 
of miltefosine treatment (/>). Epidermotropic mononuclear cells (a\ arrows) have cleared. 
Mononuclear cells are still detectable in the deeper dermis (h: arrows). 
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the topical application of cytotoxic drugs such as carmustine, but systemic 
side effects such as thrombocytopenia are common [5]. New promising 
approaches include interferon-alpha or desoxycoformycin [10, 17]. The 
clinical efficacy of these drugs remains to be determined. 
Therefore, it is necessary to search for new agents with low toxicity. 
Phospholipids are effective against a broad variety of tumor cells in vitro 
[13, 14, 18, 19,20]. In the case of hexadecylphosphocholine, which was 
introduced as antineoplastic agent by Eibl and Unger [21], this compound 
shows strong and selective antitumoral activity. The topical application is 
feasible and provides high tolerabililty [15]. We observed no systemical side 
effects during the topical application which was limited, however, to an 
area of 20 40 cm 2 in most of the patients. 
In 2 patients (13%), local inflammatory reactions caused the discon-
tinuation of the therapy. Both events occurred early (3 and 4 weeks after 
initiation) during the study period in intertriginous areas. This point 
suggests a drug-related toxicity which was probably enhanced by an 
occlusive effect due to the localization of the lesions. Allergologic testing to 
exclude sensitization, however, was not performed. 
Histological demonstration of residual infiltrates in the deeper dermis 
of clinically responding lesions indicates that cytotoxicity against the 
infiltrate seems to be restricted to the epidermis and the upper dermis. 
Limited skin penetration, clearance of the drug via dermal blood vessels, 
and local metabolic deactivation might explain this restriction of activity. 
Formulations with increased skin penetration may be expected to 
enhance local bioavailability and to facilitate cytotoxicity against deeper 
infiltrates. The determination of hexadecylphosphocholine serum levels will 
cast light on this point, especially during treatment of larger areas. 
The preliminary results reported here are promising. Miltefosine 
appears as an active agent against the infiltrating cells in cutaneous 
lymphomas. Due to the biological property of epidermotropism of these 
lymphoproliferative disorders, a topical application of cytotoxic drugs is 
suitable. This study is ongoing and it is reasonable to assume that it will 
provide data to understand in more detail the therapeutic efficacy of 
miltefosine in cutaneous lymphomas as well as in other neoplasias. 
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